An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels

Authors

  • Thies Rösner,

    1. Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany
    Search for more papers by this author
    • These authors contributed equally to the work.
  • Stefanie Derer,

    Corresponding author
    • Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany
    Search for more papers by this author
    • These authors contributed equally to the work.
  • Christian Kellner,

    1. Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany
    Search for more papers by this author
  • Michael Dechant,

    1. Department of Medicine IV, Nephrology and Hypertension, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany
    Search for more papers by this author
  • Stefan Lohse,

    1. Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany
    Search for more papers by this author
  • Gestur Vidarsson,

    1. Department of Experimental Immunohaematology, Sanquin Research, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Search for more papers by this author
  • Matthias Peipp,

    1. Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany
    Search for more papers by this author
  • Thomas Valerius

    1. Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany
    Search for more papers by this author

Correspondence: Stefanie Derer, Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University, Kiel, Schittenhelmstraße 12, 24105 Kiel, Germany.

E-mail: s.derer@med2.uni-kiel.de

Ancillary